Kerry Wentworth, Chief Regulatory Officer (CRO) of Nuvation Bio (NUVB 0.71%), reported the sale of 200,000 shares of Class A Common Stock for a total of approximately $904,000 on April 6, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 200,000 |
| Transaction value | ~$904K |
| Post-transaction shares (direct) | 53,000 |
| Post-transaction value (direct ownership) | ~$236K |
Transaction value based on SEC Form 4 weighted average purchase price ($4.52); post-transaction value based on April 6, 2026 market close ($4.45).
Key questions
- What percentage of direct Class A holdings did this sale represent?
This transaction reduced Wentworth's direct Class A Common Stock position by 79.05%, moving from 253,000 to 53,000 shares. - Was this transaction linked to derivative activity or indirect entities?
The sale followed the exercise of options with immediate disposition of shares, and involved only direct ownership with no participation by family trusts or other indirect entities. - Does Wentworth retain a material economic interest in Nuvation Bio after the sale?
Yes, Wentworth continues to hold 700,000 directly owned stock options, which, if exercised, would convert into Class A shares and restore a substantial beneficial stake. - How does the transaction relate to prior trading cadence and share capacity?
This is the first open-market sale in the recent period, with the large size explained by substantial pre-transaction holdings that allowed for liquidity without fully exiting the position.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 4/6/26) | $4.45 |
| Market capitalization | $1.59 billion |
| Revenue (TTM) | $62.90 million |
| Net income (TTM) | -$204.63 million |
* One-year performance metrics, if shown, use April 6, 2026, as the reference date.
Company snapshot
- Develops oncology-focused therapeutics, including lead candidates such as NUV-422 (CDK inhibitor), NUV-868 (BET inhibitor), and NUV-569 (Wee1 kinase inhibitor), as well as a drug-drug conjugate platform and adenosine receptor inhibitor.
- Operates a clinical-stage biopharmaceutical model, with growth dependent on clinical advancement and potential commercialization.
- Targets healthcare providers, research institutions, and pharmaceutical partners within the oncology and biotechnology markets.
Nuvation Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapeutics. With a diversified pipeline of small-molecule and targeted therapies, the company aims to address unmet medical needs in cancer treatment. The organization leverages its scientific expertise and robust research platform to advance novel drug candidates, positioning itself to compete in the evolving biotechnology sector.
What this transaction means for investors
When insiders, such as the CRO of a clinical-stage biotech, sell a large block of their own company’s shares, other investors take note. However, such sales are a normal, planned event for executives who receive stock options as part of their compensation, and this is a prime example.
Kerry Wentworth, CRO of Nuvation Bio, recently sold 200,000 shares after exercising options, thereby locking in profits. He retains 53,000 shares as well as 700,000 options, so there appears to be no connection to market sentiment around the stock’s future performance.
Nuvation Bio has promising treatments in its pipeline, as well as revenue from its oncology medication, Ibtrozi. Although the company had a full-year net loss of approximately $204.6 million, this is typical for a biotech investing heavily in R&D. Like other companies in the sector, much depends on the success of its pipeline, which makes it a stock best suited for long-term investors with a high tolerance for risk.
